drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
Autologous gene-modified T cells engineered to express a chimeric antigen receptor targeting CD19 on B cells, leading to T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of malignant CD19+ B cells.
nci_thesaurus_concept_id
C176018
nci_thesaurus_preferred_term
Anti-CD19 CAR T Cells Preparation
nci_thesaurus_definition
Any preparation of CAR-T cells that targets CD19.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting CD19 on B cells. Binding to CD19 triggers MHC-independent T-cell activation and co-stimulation, leading to T-cell expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of malignant CD19+ B cells (with on-target depletion of normal B cells).
drug_name
Anti-CD19 CAR-T cells
nct_id_drug_ref
NCT06532630